## Clinical Assessment and Management Rationale ### COPD Severity Classification **Key Point:** FEV₁ 42% predicted indicates GOLD Stage 3 (Severe) COPD. This patient requires escalated pharmacotherapy based on exacerbation risk and symptom burden. ### Triple Therapy Indication According to GOLD 2023 guidelines, triple therapy (LABA + LAMA + ICS) is indicated in: - Patients with FEV₁ < 50% predicted AND - Symptoms of chronic bronchitis or emphysema (productive cough, sputum production) AND - History of exacerbations or high exacerbation risk This patient meets all criteria: - FEV₁ 42% (< 50%) - Productive cough with sputum - Symptomatic dyspnea requiring intervention ### Management Algorithm ```mermaid flowchart TD A[COPD diagnosis confirmed<br/>FEV₁ 42% predicted]:::outcome --> B{Exacerbation history<br/>or symptoms?}:::decision B -->|No exacerbations<br/>mild symptoms| C[LABA or LAMA monotherapy]:::action B -->|≥1 exacerbation/year<br/>or symptomatic| D{FEV₁ < 50%<br/>+ chronic bronchitis?}:::decision D -->|Yes| E[Triple therapy<br/>LABA + LAMA + ICS]:::action D -->|No| F[Dual therapy<br/>LABA + LAMA]:::action E --> G[Optimize therapy<br/>Reassess in 4-8 weeks]:::action F --> G ``` ### Why Pulmonary Function Testing is Included **High-Yield:** Baseline spirometry and lung volumes (TLC, RV, IC) are essential to: - Confirm COPD diagnosis and severity - Assess reversibility (post-bronchodilator FEV₁) - Establish baseline for monitoring disease progression - Identify candidacy for future interventions (LVRS, endobronchial valves) ### Key Point: Immediate Medical Optimization Before considering surgical interventions (LVRS) or advanced diagnostics, medical therapy must be optimized. Triple therapy is the standard-of-care escalation for this severity and symptom profile. [cite:GOLD 2023 Strategy Document, Harrison 21e Ch 258]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.